Safety and efficacy of rituximab-based first line treatment of chronic GVHD-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of rituximab-based first line treatment of chronic GVHD

Published:2018-12-05 Issue:8 Volume:54 Page:1218-1226
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Solomon Scott R.,Sizemore Connie A.,Ridgeway Michelle,Zhang Xu,Brown Stacey,Holland H. Kent,Morris Lawrence E.,Solh Melhem,Bashey Asad

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/s41409-018-0399-7.pdf

Reference55 articles.

1. Abou-Mourad YR, Lau BC, Barnett MJ, Forrest DL, Hogge DE, Nantel SH, et al. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens. Bone Marrow Transplant. 2010;45:295–302.

2. Higman MA, Vogelsang GB. Chronic graft versus host disease. Br J Haematol. 2004;125:435–54.

3. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: a report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood. 2006;108:4288–90.

4. Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015;125:606–15.

5. Martin PJ, Counts GW Jr., Appelbaum FR, Lee SJ, Sanders JE, Deeg HJ, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010;28:1011–6.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Clinical Outcomes and B Cell Immune Reconstitution Following Allo-HCT With Prophylactic, Post-Transplant Rituximab;Transplantation and Cellular Therapy;2024-05

2. Dynamic forecasting module for chronic graft-versus-host disease progression based on a disease-specific subpopulation of B cells;2024-04-22

3. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases;The FASEB Journal;2024-03-12

4. Low-dose rituximab in steroid-refractory chronic graft-versus-host disease;Transplant Immunology;2023-12

5. Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases;2023-09-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3